Amgen Inc. (AMGN)

US — Healthcare Sector
Peers: MRK  ABBV  GILD  JNJ  BMY  PFE  LLY  BIIB 

Automate Your Wheel Strategy on AMGN

With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AMGN
  • Rev/Share 63.4312
  • Book/Share 11.5372
  • PB 24.5762
  • Debt/Equity 9.2446
  • CurrentRatio 1.1704
  • ROIC 0.0953

 

  • MktCap 152461159240.0
  • FreeCF/Share 20.2881
  • PFCF 13.968
  • PE 25.7112
  • Debt/Assets 0.6421
  • DivYield 0.0327
  • ROE 0.9294

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed AMGN Guggenheim -- Neutral -- $288 May 20, 2025
Resumed AMGN Cantor Fitzgerald -- Neutral -- $305 April 22, 2025
Resumed AMGN BofA Securities -- Underperform -- $256 Dec. 10, 2024
Initiation AMGN Bernstein -- Outperform -- $380 Oct. 17, 2024
Downgrade AMGN Truist Buy Hold $320 $333 Oct. 14, 2024
Initiation AMGN Cantor Fitzgerald -- Overweight -- $405 Sept. 27, 2024

News

Amgen plans $200 million investment in India site, CEO says
AMGN
Published: February 24, 2025 by: Reuters
Sentiment: Positive

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert A. Bradway said at the inauguration of the site.

Read More
image for news Amgen plans $200 million investment in India site, CEO says
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
AMGN
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
AMGN
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Amgen, Inc. (NASDAQ:AMGN ) Citi's 2025 Virtual Oncology Leadership Summit Conference Call February 19, 2025 3:00 PM ET Company Participants Jean-Charles Soria - Senior Vice President of R&D Justin Claeys - Vice President of Investor Relations Conference Call Participants Geoffrey Meacham - Citigroup Geoffrey Meacham Hello, good afternoon. My name is Geoff Meacham.

Read More
image for news Amgen, Inc. (AMGN) Citi's 2025 Virtual Oncology Leadership Summit Conference (Transcript)
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
AMGN
Published: February 14, 2025 by: PRNewsWire
Sentiment: Neutral

THOUSAND OAKS, Calif. , Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m.

Read More
image for news AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
AMGN
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral

Amgen, Inc. (NASDAQ:AMGN ) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Company Participants Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - Head of Investor Relations Casey Capparelli - Investor Relations Conference Call Participants Jay Olson - Oppenheimer & Co. Jay Olson Hello, everyone. I'm Jay Olson, one of the biotech analysts at Oppenheimer, and it's a pleasure to welcome you to Oppenheimer's 35th Annual Healthcare Conference.

Read More
image for news Amgen, Inc. (AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call Transcript
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
AMGN
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
3 Fabulous Dividend Stocks to Buy in February
ABBV, AMGN, GILD
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.

Read More
image for news 3 Fabulous Dividend Stocks to Buy in February

About Amgen Inc. (AMGN)

  • IPO Date 1983-06-17
  • Website https://www.amgen.com
  • Industry Drug Manufacturers - General
  • CEO Mr. Robert A. Bradway
  • Employees 28000

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.